**Author details**

Gabriela Roman1 \* and Anca Pantea Stoian<sup>2</sup>

1 Clinical Center of Diabetes, Nutrition and Metabolic Diseases, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania

2 Department of Diabetes, Nutrition and Metabolic Diseases, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania

\*Address all correspondence to: groman@umfcluj.ro

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**289**

*Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus DOI: http://dx.doi.org/10.5772/intechopen.97422*

> Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645. DOI:10.1161/ CIRCULATIONAHA.109.192644

[9] Ferrannini E, Cushman WC. Diabetes and hypertension: The bad companions. The Lancet, 2012;380: 601-610. DOI: 10.1016/S0140-6736(12)

[10] Xiao C, Dash S, Morgantini C et al. Pharmacological targeting of the atherogenic dyslipidemia complex: The next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes 2016;65:1767-1778. DOI: 10.2337/

[11] Eeg-Olofsson K., Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia, 2009, 52: 65. DOI: 10.1007/

[12] Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular

diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal, 2020

(41), 2: 255-323. DOI: 10.1093/

Rawshani A, Hattersley AT, Svensson AM, Eliasson B,

[13] Rawshani A, Sattar N, Franzen S,

Gudbjornsdottir S. Excess mortality and

eurheartj/ehz486

60987-8

db16-0046

s00125-008-1190-x

[1] Low Wang CC, Hess CN, Hiatt WR, et al. Clinical Update: Cardiovascular

Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management,

[2] Mensah GA., Wei GS., Sorlie PD, et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res. 2017, 120(2): 366-380. DOI: 10.1161/CIRCRESAHA.116.309115

Disease in Diabetes Mellitus

and Clinical Considerations. Circulation. 2016;133:2459. DOI: 10.1161/CIRCULATIONAHA.

[3] Harding JL, Pavkov ME,

62:3-16. DOI: 10.1007/ s00125-018-4711-2

diabetesatlas.org/upload/ resources/2019/IDF\_Atlas\_9th\_ Edition\_2019.pdf. [Accessed:

2020-09-15]

diacare.2.2.120

Magliano DJ, et al. Global trends in diabetes complications: a review of current evidenceDiabetologia. 2019;

[4] IDF DIABETES ATLAS. Ninth edition, 2019. www. https://www.

[5] Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-2038. DOI: 10.1001/ jama.1979.03290450033020

[6] Kannel WB, McGee DL. Diabetes and glucose intolerance as risk factors

Cardiovascular Risk Factors. Insights From Framingham Heart Study. Rev Esp Cardiol. 2008;61(3):299-310. DOI: 10.1016/S1885-5857(08)60118-8

[8] Alberti K.G.M.M., Eckel RH, Grundy SM., et al. Harmonizing the

for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2:120-126. DOI: 10.2337/

[7] O'Donnella CJ, Elosua R.

116.022194

**References**

*Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus DOI: http://dx.doi.org/10.5772/intechopen.97422*
